



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12P 21/06, C07K 14/00, C07H 17/00		A1	(11) International Publication Number: WO 99/45132
			(43) International Publication Date: 10 September 1999 (10.09.99)

(21) International Application Number: **PCT/US99/04441**

(22) International Filing Date: 1 March 1999 (01.03.99)

(30) Priority Data:
60/076,454 2 March 1998 (02.03.98) US

(71) Applicant (for all designated States except US): MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; Technology Licensing Office, Five Cambridge Center, Room NE 25-230, Kendall Square, Cambridge, MA 02142-1324 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KIM, Jin-Soo [KR/KR]; Samsung Biomedical Research Institute, Center for Basic Research, 50 11 won-dong, Kangnam-ku, Seoul 135-230 (KR). PABO, Carl, O. [US/US]; 15 Ircker Terrace #2, Newton, MA 02158 (US).

(74) Agents: PARENT, Annette, S. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111-3834 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: POLY ZINC FINGER PROTEINS WITH IMPROVED LINKERS

(57) Abstract

The present invention provides methods for making chimeric zinc finger proteins with improved linkers, providing zinc finger proteins with enhanced affinity and specificity.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

POLY ZINC FINGER PROTEINS WITH IMPROVED LINKERS

5

CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims priority from USSN 60/076,454, filed March 2, 1998, herein incorporated by reference in its entirety.

10

STATEMENT AS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

15

Work described herein was supported by grants PO1-CA42063, CDR-8803014 and P30-CA14051 from the National Institutes of Health, National Science Foundation and National Cancer Institute, respectively. The U.S. Government has certain rights in the invention. Work described herein was also supported by the Howard Hughes Medical Institute.

BACKGROUND OF THE INVENTION

Zinc fingers belonging to the Cys₂-His₂ family constitute one of the most common DNA-binding motifs found in eukaryotes, and these zinc fingers have provided 20 a very attractive framework for the design and selection of DNA-binding proteins with novel sequence specificities. Numerous studies have used phage display methods or design ideas to explore and systematically alter the specificity of zinc finger-DNA interactions (Desjarlais & Berg, *Proteins Struct. Funct. Genet.* 12:101-104 (1992); Desjarlais & Berg, *Proc. Natl. Acad. Sci. USA* 90:2256-2260 (1993); Rebar & Pabo, 25 *Science* 263:671-673 (1994); Jamieson *et al.*, *Biochemistry* 33:5689-5695 (1994); Choo & Klug, *Proc. Natl. Acad. Sci. USA* 91:11163-11167 (1994); Wu *et al.*, *Proc. Natl. Acad. Sci. USA* 92:344-348 (1995); and Greisman & Pabo, *Science* 275:657-661 (1997)).

Structure based computer design has been used to link Cys₂-His₂ zinc fingers with other DNA-binding domains, including other zinc finger proteins, to generate 30 hybrid proteins that recognize extended sites (Pomerantz *et al.*, *Science* 267:93-96 (1995); Kim *et al.*, *Proc. Natl. Acad. Sci. USA* 94:3616-3620 (1997)). For example, zinc finger

proteins have been linked to a GAL4 dimerization domain to develop novel homo- and hetero-dimers (Pomerantz *et al.*, *Biochemistry* 4:965-970 (1997)), and to a nuclease domain to generate novel restriction enzymes (Kim *et al.*, *Proc. Natl. Acad. Sci. USA* 93:1156-1160 (1996)). zinc finger/homeodomain fusion is being tested for potential 5 applications in gene therapy (Rivera *et al.*, *Nature Med.* 2:1028-1032 (1996)).

There also have been several attempts to increase affinity and specificity of zinc finger proteins by adding additional fingers to a three-finger protein (Rebar, (Ph.D. Thesis), *Selection Studies of Zinc Finger-NA Recognition*, Massachusetts Institute of Technology (1997); Shi, Y. (Ph.D. Thesis) *Molecular Mechanisms of Zinc Finger* 10 *Protein-Nucleic Acid Interactions*, Johns Hopkins University (1995)) or by tandemly linking two three-finger proteins (Liu *et al.*, *Proc. Natl. Acad. Sci. USA* 94:5525-5530 (1997)). However, these previous design strategies for poly-finger proteins, which all used canonical "TGEKP" linkers (linkers having the amino acid sequence threonine-glycine-glutamate-lysine-proline) to connect the additional fingers, resulted in relatively 15 modest increases in affinity. There is thus a need to develop linkers that provide enhanced affinity and specificity to chimeric zinc finger proteins.

SUMMARY OF THE INVENTION

The present invention therefore provides a method of using structure based 20 design to select flexible linkers and make chimeric zinc finger proteins with enhanced affinity and specificity. The present invention also provides a method of making chimeric zinc finger proteins that have flexible linkers of 5 amino acids or more in length to make chimeric zinc finger proteins with enhanced affinity and specificity. Zinc finger proteins made using these methods have binding affinities in the femtomolar range and provide, 25 e.g., high levels (more than about 70 fold) of transcriptional repression at a single target site. Such zinc finger proteins can be used for regulation of gene expression, e.g., as therapeutics, diagnostics, and for research applications such as functional genomics.

In one aspect, the present invention provides a method of making a chimeric zinc finger protein that binds to adjacent target sites, the method comprising the 30 steps of: (i) selecting a first and a second DNA-binding domain polypeptide of the chimeric zinc finger protein, wherein at least one of the domains comprises a zinc finger polypeptide, and wherein the first domain binds to a first target site and the second domain binds to a second target site, which target sites are adjacent; (ii) using structure-

based design to determine the physical separation between the first and second domains when they are individually bound to the first and second target sites; (iii) selecting a flexible linker that is at least 1-2 Å longer than the physical separation between the first and second domains; and (iv) fusing the first and second domains with the flexible linker, 5 thereby making a chimeric zinc finger protein that binds to adjacent target sites.

In another aspect, the present invention provides a method of making a chimeric zinc finger protein that binds to adjacent target sites, the method comprising the steps of: (i) selecting a first and a second DNA-binding domain polypeptide of the chimeric zinc finger protein, wherein at least one of the domains comprises a zinc finger 10 polypeptide, and wherein the first domain binds to a first target site and the second domain binds to a second target site, which target sites are adjacent; (ii) selecting a flexible linker that is five or more amino acids in length; and (iv) fusing the first and second domains with the flexible linker, thereby making a chimeric zinc finger protein that binds to adjacent target sites.

15 In another aspect, the present invention provides a chimeric zinc finger protein that binds to adjacent target sites, the chimeric zinc finger protein comprising: (i) a first and a second DNA-binding domain polypeptide of the chimeric zinc finger protein, wherein at least one of the domains comprises a zinc finger polypeptide, and wherein the first domain binds to a first target site and the second domain binds to a second target site, 20 which target sites are adjacent; and (ii) a flexible linker that is at least 1-2 Å longer than the physical separation between the first and second domains when they are individually bound to the first and second target sites, as determined by structure-based modeling; wherein the first and second domains are fused with the flexible linker.

25 In another aspect, the present invention provides a chimeric zinc finger protein that binds to adjacent target sites, the chimeric zinc finger protein comprising: (i) a first and a second DNA-binding domain polypeptide of the chimeric zinc finger protein, wherein at least one of the domains comprises a zinc finger polypeptide, and wherein the first domain binds to a first target site and the second domain binds to a second target site, which target sites are adjacent; and (ii) a flexible linker that is five or more amino acids in 30 length; wherein the first and second domains are fused with the flexible linker.

In one embodiment, the present invention provides nucleic acids encoding the chimeric zinc finger proteins.

In one embodiment, the first and the second domains are zinc finger polypeptides. In another embodiment, the zinc finger polypeptide is selected from the group consisting of Zif268 and NRE. In another embodiment, the zinc finger polypeptides are heterologous. In one embodiment, the first domain is a zinc finger polypeptide and the second domain comprises a heterologous DNA-binding domain polypeptide. In another embodiment, the chimeric zinc finger protein further comprises a regulatory domain polypeptide.

In one embodiment, the chimeric zinc finger protein has femtomolar affinity for the adjacent target sites. In another embodiment, the chimeric zinc finger protein has about 2-4 femtomolar affinity for the adjacent target sites.

In one embodiment, the flexible linker is 5, 8, or 11 amino acids in length. In another embodiment, the flexible linker has the sequence RQKDGERP or RQKDGGGSERP.

In one embodiment, the target sites are separated by one or two nucleotides.

In one embodiment, the adjacent target sites are separated by zero nucleotides and the flexible linker is five or six amino acids in length. In another embodiment, the adjacent target sites are separated by one nucleotide and the flexible linker is seven, eight, or nine amino acids in length. In another embodiment, the adjacent target sites are separated by two nucleotides and the flexible linker is ten, eleven, or twelve amino acids in length. In another embodiment, the adjacent target sites are separated by three nucleotides and the flexible linker is twelve or more amino acids in length.

25

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts structure-based design of a six finger peptide, 268//NRE. The cocrystal structure of the Zif268-DNA complex and the template B-DNA (used at the junction) were aligned by superimposing phosphates (Pavletich & Pabo, *Science* 252:809-817 (1991); Elrod-Erickson *et al.*, *Structure* 4:1171-1180 (1996)). In this model, two three-finger peptides bind to corresponding 9-bp sites (bases shown in white) separated by a 2 bp gap (bases shown in gray). Note that the orientation of one three-finger peptide almost exactly matches that of the other three finger peptide because one helical turn of this underwound DNA contains 11 bp.

Figure 2 depicts schematic representations of zinc finger peptides and of reporter constructs used in transfection studies described herein. Figure 2A shows zinc finger peptides. Each finger is represented with a circle. The amino acid sequence of a linker in the Zif268 peptide (which has a canonical "TGEKP" linker) is shown, and longer linkers used to connect the three-finger peptides are indicated below. In each case, the box on the left denotes the helical region and includes the second of the conserved His residues of the finger: the zigzag line denotes the first β -sheet of the next finger, which includes the first of the conserved Cys residues. Figure 2B illustrates promoters of luciferase reporter genes. The nucleotide positions of the TATA box, the start codon, and zinc finger binding sites are numbered with respect to the transcription start site (+1).

Figure 3 depicts a gel shift assay. Various amounts (0, 0.01, 0.1, and 1 nM) of the NRE peptide were incubated for 1 hour with free binding sites (lanes 1-4) or binding sites preincubated with 0.1 nM of the Zif268 peptide for 0.5 hours (lanes 5-8). The positions of the free DNA and the protein-DNA complexes are indicated.

Figure 4 depicts competition binding studies. In Figure 4A, the 268//NRE peptide (5 pM) was preincubated with various amounts (0.05, 0.5, 5 and 50 nM) of cold competitor DNAs (lanes 3-14) for 1 hour, and then a slight molar excess (over the peptide concentration) of the labeled N/Z site (608 pM) was added to the reaction mixture. Aliquots were analyzed by gel electrophoresis at various time points, and this gel shows the results after 600 hours of incubation time at room temperature. In Figure 4B, the 268//NRE (lanes 2-6) or Zif268 peptide (lanes 7-11) was mixed with the labeled N/Z site, a slight molar excess (over the peptide concentration) of unlabeled N/Z site was added (so that 70% of the labeled site would be shifted in the absence of salmon sperm DNA), and various amounts of salmon sperm DNA (0, 0.1, 1, 10, and 100 μ g/ml) were included.

25 Samples were analyzed by gel electrophoresis after 24 hours of incubation.

Figure 5 depicts graphs (Figures 5A, 5B, 5C, and 5D) illustrating transcriptional repression *in vivo* by zinc finger peptides. Human 293 cells were transfected as described (Cepek *et al.*, *Genes Dev.* 10:2079-2088 (1996)) using the calcium phosphate precipitation method. Luciferase and β -galactosidase activities were measured 48 hours later. The luciferase activities were divided by corresponding β -galactosidase activities to yield the relative luciferase activities. Repression levels (fold repression) were obtained by dividing 1) the relative luciferase activities from the cells

transfected with the empty expression plasmid by 2) those from the cells transfected with zinc finger expression plasmids. Different scales are used in graphs for the different reporters. The 68/NR, 68/NRE, 68//NR, and 68//NRE peptides are variants of six-finger fusion proteins that are missing one or two of the terminal fingers. Thus the 68/NR 5 peptide contains fingers 2 and 3 of the Zif268 peptide fused (via the shorter of the two linkers) to fingers 1 and 2 of the NRE peptide. The data represent an average of three independent experiments, and the standard error of the mean is shown.

DETAILED DESCRIPTION OF THE INVENTION

10 I. Introduction

The present invention provides a design strategy for linkers that fuse two DNA binding domains of a chimeric zinc finger protein. These linkers are flexible and longer than the canonical linkers previously used, allowing binding of the chimeric zinc finger protein to its target site without introducing any strain. The target site is typically a 15 "composite" target site," composed of two adjacent target sites that are separated by zero to 5 or more nucleotides. Each of the adjacent target sites is recognized by one DNA-binding domain of the chimeric zinc finger protein. The linker design strategy involves structure-based design to determine a minimum length for a linker between two DNA-binding domains, and then adding additional amino acids to the linker to provide at least 20 about 1-2 additional angstroms of flexibility to the linker. The present invention thus provides chimeric zinc finger proteins with femtomolar affinity for their target site, and which effectively repress gene expression, e.g., more than about 70 fold, when targeted to a single site.

Structural and biochemical analyses show that DNA often is slightly 25 unwound when bound to zinc finger peptides (Pavletich & Pabo, *Science* 252:809-817 (1991); Shi & Berg, *Biochemistry* 35:3845-3848 (1996); Nekludova & Pabo, *Proc. Natl. Acad. Sci. USA* 91:6948-6952 (1994)). Modeling studies have shown that on ideal B DNA, the canonical linker is a bit too short to allow favorable docking of Zif268 (Elrod-Erickson et al., *Structure* 4:1171-1180 (1996)); the DNA must be slightly unwound to 30 interact with zinc fingers in the mode seen in the Zif268 complex. Essentially, it appears that the helical periodicity of the zinc fingers does not quite match the helical periodicity of B-DNA. Since the strain of unwinding may become a more serious problem when there are more fingers (the helical periodicities of the peptide and DNA may get

progressively further out of phase), longer, more flexible linkers were tested in the design of poly-finger proteins (see Kim & Pabo, *Proc. Nat'l Acad. Sci. U.S.A.* 95:2812-2817 (1998), herein incorporated by reference in its entirety).

The present invention demonstrates that linkers of 5 amino acids or more
5 can be used to make chimeric zinc finger proteins with enhanced affinity. For example, a linker of 8 amino acids was used for a chimeric zinc finger protein that recognized adjacent target sites separated by one base pair. A linker of 11 amino acids was used for a chimeric zinc finger protein that recognized adjacent target sites separated by two base pairs. The linkers of the invention can also be designed using structure-based modeling.
10 In structure-based modeling, a model is made that shows the binding of each DNA binding domain polypeptide to its DNA target site. The model is then used to determine the physical separation of the domains as they are bound to adjacent target sites. The physical separation between the domains is used to determine the minimum length of the linker used to connect the C-terminal amino acid of the first domain with the N-terminal
15 amino acid of the second domain, without steric hindrance to the linker or the DNA binding domains. This length is then increased by 1-2 Å, to create a slightly longer, flexible linker that avoids introducing strain to the chimeric zinc finger protein.

Often computer programs are used for structure-based modeling, although
the models can also be made physically. Examples of computer programs used for
20 structure-based modeling include Insight II (Biosym Technologies, SanDiego) and Quanta 4.0 (Molecular Simulations (Burlington, MA). The programs often use information derived from x-ray crystallographic studies of DNA-binding proteins to provide the appropriate coordinates for proteins. This information can also be obtained from publicly available databases such as the Brookhaven Protein Data Bank. This
25 information can also be used to extrapolate distances and coordinates for DNA binding proteins whose crystal structure is unknown. Models of B DNA are well known in the art. The relevant coordinates (e.g., distances and sizes) are used with computer modeling program of choice, using the manufacturer's instructions and default parameters.

Alternatively, customized parameters can be used. Structure-based modeling can be
30 performed as described in, e.g., Kim & Pabo, *Proc. Nat'l. Acad. Sci. U.S.A.* 95:2812-2817 (1998); Pavletich & Pabo, *Science* 252:809-817 (1991); Rebar, Ph.D. Thesis (Massachusetts Institute of Technology, Cambridge MA) (1997); Liu *et al.*, *Proc. Nat'l. Acad. Sci. U.S.A.* 94:5525-5530 (1997); Pomerantz *et al.*, *Science* 267:93-96 (1995);

Pomerantz *et al.*, *Proc. Nat'l. Acad. Sci. U.S.A.* 92:9752-9756 (1995); Li *et al.*, *Nature Biotechnology* 16:190-195 (1998); Kim *et al.*, *Proc. Natl. Acad. Sci. USA* 94:3616-3620 (1997); and Pomerantz *et al.*, *Biochemistry* 4:965-970 (1997), herein incorporated by reference in their entirety). Two basic criteria suggest which alignments of DNA-binding domains have potential for combination in a chimeric protein which binds DNA: (1) lack of collision between domains, and (2) consistent positioning of the carboxyl- and amino-terminal regions of the domains, i.e., the domains are oriented such that the carboxyl-terminal region of one polypeptide can be joined to the amino-terminal region of the next polypeptide

The linker used to link the two DNA-binding domains can comprise any amino acid sequence that does not substantially hinder interaction of the DNA-binding domains with their respective target sites. Preferred amino acid residues for linkers of the present invention include, but are not limited to glycine, alanine, leucine, serine, valine and threonine. Once the length of the amino acid sequence has been selected, the sequence of the linker can be selected, e.g., by phage display library technology (see, e.g., U.S. Patent No. 5,260,203), or using naturally occurring or synthetic linker sequences as a scaffold (e.g., GTGQKP and GEKP, see Liu *et al.*, *Proc. Nat'l Acad. Sci. U.S.A.* 94:5525-5530 (1997); see also Whitlow *et al.*, *Methods: A Companion to Methods in Enzymology* 2:97-105 (1991)). Typically, the linkers of the invention are made by making recombinant nucleic acids encoding the linker and the DNA-binding domains, which are fused via the linker amino acid sequence. Optionally, the linkers can also be made using peptide synthesis, and then linked to the polypeptide DNA-binding domains.

The chimeric zinc finger proteins of the invention are composed of two or more DNA-binding domains, where at least one of the DNA binding domains is a zinc finger polypeptide. The second DNA binding domain can be a zinc finger binding domain, either the same domain or a heterologous domain. Suitable zinc finger proteins include any protein from the Cys₂-His₂ family, e.g., SP-1, SP-1C, ZIF268, NRE, Tramtrack, GLI, YY1, or TFIIIA (see, e.g., Jacobs, *EMBO J.* 11:4507 (1992); Desjarlais & Berg, *PNAS* 90:2256-2260 (1993); Christy *et al.*, *PNAS* 85:7857-7861 (1988); Greisman & Pabo, *Science* 275:657-661 (1997); Fairall *et al.*, *Nature* 366:483 (1993); Paveltich *et al.*, *Science* 261:1701 (1993)).

The second DNA binding domain can also be a heterologous DNA binding domain, e.g., from a restriction enzyme; a nuclear hormone receptor; a homeodomain

protein or a helix turn helix motif protein such as MAT 1, MAT 2, MAT a1, Antennapedia, Ultrabithorax, Engrailed, Paired, Fushi tarazu, HOX, Unc86, Oct1, Oct2, Pit, lambda repressor and tet repressor; Gal 4; TATA binding protein; helix loop helix motif proteins such as myc, myo D, Daughterless, Achaete-scute (T3), E12, and E47; 5 leucine zipper type proteins such as GCN4, C/EBP, c-Fos/c-Jun and JunB; and beta sheet motif proteins such as met, arc, and mnt repressors. In another embodiment, the zinc finger protein is linked to at least one or more regulatory domains, described below. Preferred regulatory domains include transcription factor repressor or activator domains such as KRAB and VP16, co-repressor and co-activator domains, DNA methyl 10 transferases, histone acetyltransferases, histone deacetylases, and endonucleases such as Fok1. The amino acid sequences of the DNA-binding domains may be naturally- occurring or non-naturally-occurring (or modified).

The expression of chimeric zinc finger proteins can be also controlled by systems typified by the tet-regulated systems and the RU-486 system (see, e.g., Gossen & 15 Bujard, PNAS 89:5547 (1992); Oligino *et al.*, *Gene Ther.* 5:491-496 (1998); Wang *et al.*, *Gene Ther.* 4:432-441 (1997); Neering *et al.*, *Blood* 88:1147-1155 (1996); and Rendahl *et al.*, *Nat. Biotechnol.* 16:757-761 (1998)). These impart small molecule control on the expression of the chimeric zinc finger protein and thus impart small molecule control on the target gene(s) of interest. This beneficial feature could be used in cell culture models, 20 in gene therapy, and in transgenic animals and plants.

The binding specificity of the chimeric DNA-binding proteins makes them particularly useful because they have DNA-binding properties distinct from those of known proteins. The chimeric proteins prefer to bind the adjacent target sites and, thus, can be used to modulate expression of genes having the adjacent target sites. These 25 chimeric zinc finger proteins have an affinity for the adjacent target sites that is in the femtomolar range, e.g., 100 femtomoles, 10 femtomoles, or less, in some cases as low as 2-4 femtomoles, and in some cases 1 femtomolar or lower.

The zinc finger proteins made using the method of the invention have numerous applications, including therapeutic, diagnostic, and research applications such 30 as in cell or animal models and functional genomics. For example, zinc finger proteins can be used to regulate gene expression, allowing for novel human and mammalian therapeutic applications, e.g., treatment of genetic diseases, cancer, fungal, protozoal, bacterial, and viral infection, ischemia, vascular disease, arthritis, immunological

disorders, etc., as well as providing means for developing plants with altered phenotypes, including disease resistance, fruit ripening, sugar and oil composition, yield, and color. In addition, the zinc finger proteins of the present invention can be used for diagnostic assays and for functional genomics assays.

5 As described herein, zinc finger proteins can be designed to recognize any suitable target site for any of the uses described herein, e.g., eukaryotic and prokaryotic genes, cellular genes, viral genes, protozoal genes, fungal genes, and bacterial genes. In general, suitable genes to be regulated include cytokines, lymphokines, growth factors, mitogenic factors, chemotactic factors, onco-active factors, receptors, potassium
10 channels, G-proteins, signal transduction molecules, and other disease-related genes.

A general theme in transcription factor function is that simple binding and sufficient proximity to the promoter are all that is generally needed. Exact positioning relative to the promoter, orientation, and within limits, distance do not matter greatly. This feature allows considerable flexibility in choosing sites for constructing zinc finger
15 proteins. The target site recognized by the zinc finger protein therefore can be any suitable site in the target gene that will allow activation or repression of gene expression by a zinc finger protein, optionally linked to a regulatory domain.

Preferred target sites include regions adjacent to, downstream, or upstream of the transcription start site. In addition, target sites that are located in enhancer regions, 20 repressor sites, RNA polymerase pause sites, and specific regulatory sites (e.g., SP-1 sites, hypoxia response elements, nuclear receptor recognition elements, p53 binding sites), sites in the cDNA encoding region or in an expressed sequence tag (EST) coding region. As described below, typically each finger recognizes 2-4 base pairs, with a two finger zinc finger protein binding to a 4 to 7 bp target site, a three finger zinc finger
25 protein binding to a 6 to 10 base pair site, and a six finger zinc finger protein binding to two adjacent target sites, each target site having from 6-10 base pairs.

Chimeric zinc finger proteins of the invention can be tested for activity *in vivo* using a simple assay (*Current Protocols in Molecular Biology* (Ausubel *et al.*, eds, 1994)). The *in vivo* assay uses a plasmid encoding the chimeric zinc finger protein,
30 which is co-expressed with a reporter plasmid containing a test gene, e.g., the luciferase gene, the chloramphenicol acetyl transferase (CAT) gene or the human growth hormone (hGH) gene, with a target site for the chimeric zinc finger protein. The two plasmids are introduced together into host cells. A second group of cells serves as the control group

and receives a plasmid encoding the transcription factor and a plasmid containing the reporter gene without the binding site for the transcription factor.

The production of reporter gene transcripts or the amount of activity of the relevant protein is measured; if mRNA synthesis from the reporter gene or the amount of activity of the relevant protein is greater than that of the control gene, the transcription factor is a positive regulator of transcription. If reporter gene mRNA synthesis or the amount of activity of the relevant protein is less than that of the control, the transcription factor is a negative regulator of transcription.

10 Optionally, the assay may include a transfection efficiency control plasmid. This plasmid expresses a gene product independent of the reporter gene, and the amount of this gene product indicates roughly how many cells are taking up the plasmids and how efficiently the DNA is being introduced into the cells. The chimeric zinc finger protein can also be tested for modulation of an endogenous gene *in vivo*, using methods known to those of skill in the art.

15 In one embodiment, the present invention provides a fusion in which the three-finger Zif268 peptide was linked to a designed three-finger peptide (designated "NRE") that specifically recognizes a nuclear hormone response element (Greisman & Pabo, *Science* 275:657 (1997)). Gel shift assays indicate that this six-finger peptide, 268//NRE, binds to a composite 18 bp DNA site with a dissociation constant in the 20 femtomolar range. The slightly longer linkers used in this fusion protein provide a dramatic improvement in DNA-binding affinity, working much better than the canonical "TGEKP" linkers that have been used in previous studies. Tissue culture transfection experiments also show that the 268//NRE peptide is an extremely effective repressor, giving 72-fold repression when targeted to a binding site close to the transcription start 25 site. Using this strategy and linking peptides selected via phage display allows the design of novel DNA-binding proteins with extraordinary affinity and specificity for use in biological applications and gene therapy.

30 The new six-finger peptides bind far more tightly than previously reported poly-finger proteins which used a conventional "TGEKP" linker to connect two three-finger modules or to add additional fingers to a three-finger protein. Poly-finger proteins with canonical linkers had been tested by Rebar (Rebar, (Ph.D. Thesis), *Selection Studies of Zinc Finger-DNA Recognition*, Massachusetts Institute of Technology (1997)), by Shi (Shi, (Ph.D. Thesis), *Molecular Mechanisms of Zinc Finger Protein-Nucleic Acid*

Interactions, Johns Hopkins University (1995)), and by Liu *et al.* (Liu *et al.*, *Proc. Natl. Acad. Sci. USA* 94:5525-5530 (1997)). Each study compared binding of the new poly-finger protein (at the appropriate extended site) with binding of the original three-finger peptide. Using canonical linkers, a four-finger peptide bound 6.3 times more tightly than the corresponding three-finger peptide (Rebar (Ph.D. Thesis), *Selection Studies of Zinc Finger-DNA Recognition*, Massachusetts Institute of Technology (1997)), a five-finger construct showed no improvement in K_d over the original three-finger peptide (Shi, (Ph.D. Thesis), *Molecular Mechanisms of Zinc Finger Protein-Nucleic Acid Interactions*, Johns Hopkins University (1995)), and six-finger peptides bound 58-74-fold more tightly than the corresponding three-finger peptides (Liu *et al.*, *Proc. Natl. Acad. Sci. USA* 94:5525-5530 (1997)).

In contrast, the peptides described herein (see Example section) bind 6,000-90,000-fold more tightly than the original three-finger peptides. It seems likely that the longer linkers used in the 268/NRE and 268//NRE constructs must relieve some strain that accumulates when a larger set of fingers all are connected with canonical linkers. Presumably this involves a slight mismatch in the helical periodicity of the DNA and the preferred helical periodicity of the zinc fingers, causing them to fall slightly out of register, particularly when 4 or more fingers are connected via canonical linkers.

20 II. Definitions

As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

The term "zinc finger protein" or "ZFP" or "zinc finger polypeptide" refers to a protein having DNA binding domains that are stabilized by zinc. The individual DNA binding domains are typically referred to as "fingers". A zinc finger protein has least one finger, typically two fingers, three fingers, or six fingers. Each finger binds from two to four base pairs of DNA, typically three or four base pairs of DNA (the "subsite"). A zinc finger protein binds to a nucleic acid sequence called a target site or target segment. Each finger typically comprises an approximately 30 amino acid, zinc-chelating, DNA-binding subdomain. An exemplary motif characterizing one class of these proteins (C₂H₂ class) is -Cys-(X)₂₋₄-Cys-(X)₁₂-His-(X)₃₋₅-His (where X is any amino acid). Studies have demonstrated that a single zinc finger of this class consists of an alpha helix containing the two invariant histidine residues co-ordinated with zinc

along with the two cysteine residues of a single beta turn (see, e.g., Berg & Shi, *Science* 271:1081-1085 (1996)).

5 A "chimeric" zinc finger protein refers to a protein that has at least two DNA-binding domains, one of which is a zinc finger polypeptide, linked to the other domain via a flexible linker. The two domains can be the same or heterologous. Both domains can be zinc finger proteins, either the same zinc finger protein or heterologous zinc finger proteins. Alternatively, one domain can be a heterologous DNA-binding protein.

10 A "target site" is the nucleic acid sequence recognized by a zinc finger protein or a heterologous DNA-binding polypeptide. For a zinc finger protein, a single target site typically has about four to about ten base pairs. Typically, a two-fingered zinc finger protein recognizes a four to seven base pair target site, a three-fingered zinc finger protein recognizes a six to ten base pair target site, and a six fingered zinc finger protein recognizes two adjacent nine to ten base pair target sites.

15 A "subsite" is a subsequence of the target site, and corresponds to a portion of the target site recognized by a single finger, e.g., a 2-4 base subsite, typically a 3 base subsite. A target site comprises at least two, typically three, four, five, six or more subsites, one for each finger of the protein.

20 The term "adjacent target sites" refers to non-overlapping target sites that are separated by zero to about 5 base pairs.

25 The "physical separation" between two DNA-binding domains refers to the distance between two domains when they are bound to their respective target sites. This distance is used to determine a minimum length of a linker. A minimum length of a linker is the length that would allow the two domains to be connected without providing steric hindrance to the domains or the linker (a minimum linker). A linker that provides more than the minimum length is a "flexible linker."

"Structure based design" refers to methods of determining the length of minimum linkers and flexible linkers, using physical or computer models of DNA-binding proteins bound to their respective target sites.

30 " K_d " refers to the dissociation constant for the compound, i.e., the concentration of a compound (e.g., a zinc finger protein) that gives half maximal binding of the compound to its target (i.e., half of the compound molecules are bound to the target) under given conditions (i.e., when $[\text{target}] \ll K_d$), as measured using a given assay

system (see, e.g., U.S. Patent No. 5,789,538). The assay system used to measure the K_d should be chosen so that it gives the most accurate measure of the actual K_d of the zinc finger protein. Any assay system can be used, as long as it gives an accurate measurement of the actual K_d of the zinc finger protein. In one embodiment, the K_d for the zinc finger proteins of the invention is measured using an electrophoretic mobility shift assay ("EMSA"), as described in herein. Unless an adjustment is made for zinc finger protein purity or activity, K_d calculations may result in an underestimate of the true K_d of a given zinc finger protein.

The phrase "adjacent to a transcription initiation site" refers to a target site that is within about 50 bases either upstream or downstream of a transcription initiation site. "Upstream" of a transcription initiation site refers to a target site that is more than about 50 bases 5' of the transcription initiation site (i.e., in the non-transcribed region of the gene).

The phrase "RNA polymerase pause site" is described in Uptain *et al.*, *Annu. Rev. Biochem.* 66:117-172 (1997).

The term "heterologous" is a relative term, which when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, a nucleic acid that is recombinantly produced typically has two or more sequences from unrelated genes synthetically arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. The two nucleic acids are thus heterologous to each other in this context. When added to a cell, the recombinant nucleic acids would also be heterologous to the endogenous genes of the cell. Thus, in a chromosome, a heterologous nucleic acid would include an non-native (non-naturally occurring) nucleic acid that has integrated into the chromosome, or a non-native (non-naturally occurring) extrachromosomal nucleic acid. In contrast, a naturally translocated piece of chromosome would not be considered heterologous in the context of this patent application, as it comprises an endogenous nucleic acid sequence that is native to the mutated cell.

A "regulatory domain" refers to a protein or a protein domain that has an activity such as transcriptional modulation activity, DNA modifying activity, protein modifying activity and the like when tethered to a DNA binding domain, i.e., a zinc finger protein. Examples of regulatory domains include proteins or effector domains of

proteins, e.g., transcription factors and co-factors (e.g., KRAB, MAD, ERD, SID, nuclear factor kappa B subunit p65, early growth response factor 1, and nuclear hormone receptors, VP16, VP64), endonucleases, integrases, recombinases, methyltransferases, histone acetyltransferases, histone deacetylases etc. Activators and repressors include co-activators and co-repressors (see, e.g., Utley *et al.*, *Nature* 394:498-502 (1998)).

A "heterologous DNA-binding domain" refers to a DNA binding domain from a protein that is not a zinc finger protein, such restriction enzyme, a nuclear hormone receptor, a homeodomain protein such as engrailed or antenopedia, a bacterial helix turn helix motif protein such as lambda repressor and tet repressor, Gal 4, TATA binding protein, helix loop helix motif proteins such as myc and myo D, leucine zipper type proteins such as fos and jun, and beta sheet motif proteins such as met, arc, and mnt repressors.

"Humanized" refers to a non-human polypeptide sequence that has been modified to minimize immunoreactivity in humans, typically by altering the amino acid sequence to mimic existing human sequences, without substantially altering the function of the polypeptide sequence (see, e.g., Jones *et al.*, *Nature* 321:522-525 (1986), and published UK patent application No. 8707252). Backbone sequences for the zinc finger proteins are preferably be selected from existing human C₂H₂ zinc finger proteins (e.g., SP-1). Functional domains are preferably selected from existing human genes, (e.g., the activation domain from the p65 subunit of NF-κB). Where possible, the recognition helix sequences will be selected from the thousands of existing zinc finger protein DNA recognition domains provided by sequencing the human genome. As much as possible, domains will be combined as units from the same existing proteins. All of these steps will minimize the introduction of new junctional epitopes in the chimeric zinc finger proteins and render the engineered zinc finger proteins less immunogenic.

"Nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs). Unless

otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and 5 polynucleotide. The nucleotide sequences are displayed herein in the conventional 5'-3' orientation.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an analog or mimetic of a 10 corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. Polypeptides can be modified, e.g., by the addition of carbohydrate residues to form glycoproteins. The terms "polypeptide," "peptide" and "protein" include glycoproteins, as well as non-glycoproteins. The polypeptide sequences are displayed herein in the conventional N-terminal to C-terminal orientation.

15 The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to 20 compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine, and methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino 25 acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively 30 modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Specifically, degenerate codon substitutions

may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer *et al.*, *Nucleic Acid Res.* 19:5081 (1991); Ohtsuka *et al.*, *J. Biol. Chem.* 260:2605-2608 (1985); Rossolini *et al.*, *Mol. Cell. Probes* 8:91-98 (1994)). Because of the

5 degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon in an amino acid herein, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations

10 are "silent variations," which are one species of conservatively modified variations.

Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally 15 identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.

As to amino acid and nucleic acid sequences, individual substitutions, deletions or additions that alter, add or delete a single amino acid or nucleotide or a small percentage of amino acids or nucleotides in the sequence create a "conservatively 20 modified variant," where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants and alleles of the invention.

The following groups each contain amino acids that are conservative 25 substitutions for one another:

- 1) Alanine (A), Glycine (G);
- 2) Serine (S), Threonine (T);
- 3) Aspartic acid (D), Glutamic acid (E);
- 4) Asparagine (N), Glutamine (Q);
- 30 5) Cysteine (C), Methionine (M);
- 6) Arginine (R), Lysine (K), Histidine (H);
- 7) Isoleucine (I), Leucine (L), Valine (V); and
- 8) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

(*see, e.g.*, Creighton, *Proteins* (1984) for a discussion of amino acid properties).

III. Design of Zinc Finger Proteins

5 The chimeric zinc finger proteins of the invention comprise at least one zinc finger polypeptide linked via a flexible linker to at least a second DNA binding domain, which optionally is a second zinc finger polypeptide. The chimeric zinc finger protein may contain more than two DNA-binding domains, as well as one or more regulator domains. The zinc finger polypeptides of the invention can be engineered to
10 recognize a selected target site in the gene of choice. Typically, a backbone from any suitable C₂H₂ ZFP, such as SP-1, SP-1C, or ZIF268, is used as the scaffold for the engineered zinc finger polypeptides (*see, e.g.*, Jacobs, *EMBO J.* 11:4507 (1992); Desjarlais & Berg, *PNAS* 90:2256-2260 (1993)). A number of methods can then be used
15 to design and select a zinc finger polypeptide with high affinity for its target. A zinc finger polypeptide can be designed or selected to bind to any suitable target site in the target gene, with high affinity. Co-pending patent application USSN _____, filed
January 12, 1999 (TTC attorney docket no. 019496-001800, herein incorporated by reference), comprehensively describes methods for design, construction, and expression
20 of zinc finger polypeptides for selected target sites.

Any suitable method known in the art can be used to design and construct
nucleic acids encoding zinc finger polypeptides, e.g., phage display, random mutagenesis,
combinatorial libraries, computer/rational design, affinity selection, PCR, cloning from
cDNA or genomic libraries, synthetic construction and the like. (*see, e.g.*, U.S. Pat. No.
5,786,538; Wu *et al.*, *PNAS* 92:344-348 (1995); Jamieson *et al.*, *Biochemistry* 33:5689-
25 5695 (1994); Rebar & Pabo, *Science* 263:671-673 (1994); Choo & Klug, *PNAS*
91:11163-11167 (1994); Choo & Klug, *PNAS* 91: 11168-11172 (1994); Desjarlais &
Berg, *PNAS* 90:2256-2260 (1993); Desjarlais & Berg, *PNAS* 89:7345-7349 (1992);
Pomerantz *et al.*, *Science* 267:93-96 (1995); Pomerantz *et al.*, *PNAS* 92:9752-9756
(1995); and Liu *et al.*, *PNAS* 94:5525-5530 (1997); Griesman & Pabo, *Science* 275:657-
30 661 (1997); Desjarlais & Berg, *PNAS* 91:11-99-11103 (1994)).

In a preferred embodiment, copending application USSN _____, filed
January 12, 1999 (TTC attorney docket no. 019496-001800) provides methods that select
a target gene, and identify a target site within the gene containing one to six (or more) D-

able sites (see definition below). Using these methods, a zinc finger polypeptide can then be synthesized that binds to the preselected site. These methods of target site selection are premised, in part, on the recognition that the presence of one or more D-able sites in a target segment confers the potential for higher binding affinity in a zinc finger

5 polypeptide selected or designed to bind to that site relative to zinc finger polypeptides that bind to target segments lacking D-able sites.

A D-able site or subsite is a region of a target site that allows an appropriately designed single zinc finger to bind to four bases rather than three of the target site. Such a zinc finger binds to a triplet of bases on one strand of a double-stranded target segment (target strand) and a fourth base on the other strand (see Figure 2 of copending application USSN _____, filed January 12, 1999 (TTC attorney docket no. 019496-001800). Binding of a single zinc finger to a four base target segment imposes constraints both on the sequence of the target strand and on the amino acid sequence of the zinc finger. The target site within the target strand should include the "D-able" site motif 5' NNGK 3', in which N and K are conventional IUPAC-IUB ambiguity codes. A zinc finger for binding to such a site should include an arginine residue at position -1 and an aspartic acid, (or less preferably a glutamic acid) at position +2. The arginine residues at position -1 interacts with the G residue in the D-able site. The aspartic acid (or glutamic acid) residue at position +2 of the zinc finger interacts with the opposite strand

10 base complementary to the K base in the D-able site. It is the interaction between aspartic acid (symbol D) and the opposite strand base (fourth base) that confers the name D-able site. As is apparent from the D-able site formula, there are two subtypes of D-able sites: 5' NN₂G 3' and 5' NN₂T 3'. For the former site, the aspartic acid or glutamic acid at position +2 of a zinc finger interacts with a C in the opposite strand to the D-able site. In

15 the latter site, the aspartic acid or glutamic acid at position +2 of a zinc finger interacts with an A in the opposite strand to the D-able site. In general, NN₂G is preferred over NN₂T.

20

25

In the design of a zinc finger polypeptide with three fingers, a target site should be selected in which at least one finger of the protein, and optionally, two or all

30 three fingers have the potential to bind a D-able site. Such can be achieved by selecting a target site from within a larger target gene having the formula 5'-NN_x aN_y bN_zc-3', wherein

each of the sets (x, a), (y, b) and (z, c) is either (N, N) or (G, K);
at least one of (x, a), (y, b) and (z, c) is (G, K). and
N and K are IUPAC-IUB ambiguity codes

5 In other words, at least one of the three sets (x, a), (y, b) and (z, c) is the set (G, K), meaning that the first position of the set is G and the second position is G or T. Those of the three sets (if any) which are not (G, K) are (N, N), meaning that the first position of the set can be occupied by any nucleotide and the second position of the set can be occupied by any nucleotide. As an example, the set (x, a) can be (G, K) and the
10 sets (y, b) and (z, c) can both be (N, N).

In the formula 5'-NNx aNy bNzc-3', the triplets of NNx aNy and bNzc represent the triplets of bases on the target strand bound by the three fingers in a zinc finger polypeptide. If only one of x, y and z is a G, and this G is followed by a K, the target site includes a single D-able subsite. For example, if only x is G, and a is K, the
15 site reads 5'-**NNG** KNy bNzc-3' with the D-able subsite highlighted. If both x and y but not z are G, and a and b are K, then the target site has two overlapping D-able subsites as follows: 5'-**NNG** *KNG* KNz c-3', with one such site being represented in bold and the other in italics. If all three of x, y and z are G and a, b, and c are K, then the target
segment includes three D-able subsites, as follows 5'**NNG** *KNG* KNG K3', the D-able
20 subsites being represented by bold, italics and underline.

These methods thus work by selecting a target gene, and systematically searching within the possible subsequences of the gene for target sites conforming to the formula 5'-NNx aNy bNzc-3', as described above. In some such methods, every possible subsequence of 10 contiguous bases on either strand of a potential target gene is evaluated
25 to determine whether it conforms to the above formula, and, if so, how many D-able sites are present. Typically, such a comparison is performed by computer, and a list of target sites conforming to the formula are output. Optionally, such target sites can be output in different subsets according to how many D-able sites are present.

In a variation, the methods of the invention identify first and second target
30 segments, each independently conforming to the above formula. The two target segments in such methods are constrained to be adjacent or proximate (i.e., within about 0-5 bases) of each other in the target gene. The strategy underlying selection of proximate target segments is to allow the design of a zinc finger polypeptide formed by linkage of two

component zinc finger polypeptides specific for the first and second target segments respectively. These principles can be extended to select target sites to be bound by zinc finger polypeptides with any number of component fingers. For example, a suitable target site for a nine finger protein would have three component segments, each

5 conforming to the above formula.

The target sites identified by the above methods can be subject to further evaluation by other criteria or can be used directly for design or selection (if needed) and production of a zinc finger polypeptide specific for such a site. A further criteria for evaluating potential target sites is their proximity to particular regions within a gene. If a

10 zinc finger polypeptide is to be used to repress a cellular gene on its own (i.e., without linking the zinc finger polypeptide to a repressing moiety), then the optimal location appears to be at, or within 50 bp upstream or downstream of the site of transcription initiation, to interfere with the formation of the transcription complex (Kim & Pabo, *J. Biol. Chem.* 272:29795-296800 (1997)) or compete for an essential enhancer binding

15 protein. If, however, a zinc finger polypeptide is fused to a functional domain such as the KRAB repressor domain or the VP16 activator domain, the location of the binding site is considerably more flexible and can be outside known regulatory regions. For example, a KRAB domain can repress transcription at a promoter up to at least 3 kbp from where KRAB is bound (Margolin *et al.*, *PNAS* 91:4509-4513 (1994)). Thus, target sites can be

20 selected that do not necessarily include or overlap segments of demonstrable biological significance with target genes, such as regulatory sequences. Other criteria for further evaluating target segments include the prior availability of zinc finger polypeptide s binding to such segments or related segments, and/or ease of designing new zinc finger polypeptides to bind a given target segment.

25 After a target segment has been selected, a zinc finger polypeptide that binds to the segment can be provided by a variety of approaches. The simplest of approaches is to provide a precharacterized zinc finger polypeptide from an existing collection that is already known to bind to the target site. However, in many instances, such zinc finger polypeptides do not exist. An alternative approach can also be used to

30 design new v zinc finger polypeptides, which uses the information in a database of existing zinc finger polypeptides and their respective binding affinities. A further approach is to design a zinc finger polypeptide based on substitution rules as discussed above. A still further alternative is to select a zinc finger polypeptide with specificity for

a given target by an empirical process such as phage display. In some such methods, each component finger of a zinc finger polypeptide is designed or selected independently of other component fingers. For example, each finger can be obtained from a different preexisting zinc finger polypeptide or each finger can be subject to separate

5 randomization and selection.

Once a zinc finger polypeptide has been selected, designed, or otherwise provided to a given target segment, the zinc finger polypeptide or the DNA encoding it are synthesized. Exemplary methods for synthesizing and expressing DNA encoding zinc finger proteins are described below. The zinc finger polypeptide or a polynucleotide

10 encoding it can then be used for modulation of expression, or analysis of the target gene containing the target site to which the zinc finger polypeptide binds.

IV. Expression and purification of zinc finger proteins made using the methods of the invention

15 Chimeric zinc finger proteins comprising a flexible linker and nucleic acids encoding such chimeric zinc finger proteins can be made using routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods of use in this invention include Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd ed. 1989); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and

20 *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., 1994)). In addition, essentially any nucleic acid can be custom ordered from any of a variety of commercial sources. Similarly, peptides and antibodies can be custom ordered from any of a variety of commercial sources.

25 Two alternative methods are typically used to create the coding sequences required to express newly designed DNA-binding polypeptides and the flexible linker. One protocol is a PCR-based assembly procedure that utilizes six overlapping oligonucleotides (to make one three finger zinc finger polypeptide). Three oligonucleotides correspond to “universal” sequences that encode portions of the DNA-binding domain between the recognition helices. These oligonucleotides remain constant

30 for all zinc finger constructs. The other three “specific” oligonucleotides are designed to encode the recognition helices. These oligonucleotides contain substitutions primarily at positions -1, 2, 3 and 6 on the recognition helices making them specific for each of the different zinc fingers.

To make a three finger zinc finger polypeptide, the PCR synthesis is carried out in two steps. First, a double stranded DNA template is created by combining the six oligonucleotides (three universal, three specific) in a four cycle PCR reaction with a low temperature annealing step, thereby annealing the oligonucleotides to form a DNA 5 "scaffold." The gaps in the scaffold are filled in by high-fidelity thermostable polymerase, the combination of Taq and Pfu polymerases also suffices. In the second phase of construction, the zinc finger template is amplified by external primers designed to incorporate restriction sites at either end for cloning into a shuttle vector or directly into an expression vector.

10 An alternative method of cloning the newly designed DNA-binding proteins relies on annealing complementary oligonucleotides encoding the specific regions of the desired chimeric zinc finger protein. This particular application requires that the oligonucleotides be phosphorylated prior to the final ligation step. This is usually performed before setting up the annealing reactions, but kinasing can also occur post- 15 annealing. In brief, the "universal" oligonucleotides encoding the constant regions of the proteins (oligos 1, 2 and 3 of above) are annealed with their complementary oligonucleotides. Additionally, the "specific" oligonucleotides encoding the finger recognition helices are annealed with their respective complementary oligonucleotides. These complementary oligos are designed to fill in the region which was previously filled 20 in by polymerase in the protocol described above. The complementary oligos to the common oligos 1 and finger 3 are engineered to leave overhanging sequences specific for the restriction sites used in cloning into the vector of choice. The second assembly 25 protocol differs from the initial protocol in the following aspects: the "scaffold" encoding the newly designed ZFP is composed entirely of synthetic DNA thereby eliminating the polymerase fill-in step, additionally the fragment to be cloned into the vector does not require amplification. Lastly, the design of leaving sequence-specific overhangs eliminates the need for restriction enzyme digests of the inserting fragment.

30 The resulting fragment encoding the newly designed zinc finger polypeptide is ligated into an expression vector. The sequences encoding the flexible linker and the second DNA-binding domain (optionally a zinc finger polypeptide) are also ligated into the vector to create a chimeric zinc finger proteins. Typically, the flexible linker is encoded by a oligonucleotide that is ligated into the expression vector between the two DNA binding domains. The second DNA binding domain can be made as

described above, or can be cloned or obtained from an alternative source using methods well known in the art, e.g., PCR and the like. Expression vectors that are commonly utilized include, but are not limited to, a modified pMAL-c2 bacterial expression vector (New England BioLabs, "NEB") or a eukaryotic expression vector, pcDNA (Promega).

5 The nucleic acid encoding the chimeric zinc finger protein of choice is typically cloned into intermediate vectors for transformation into prokaryotic or eukaryotic cells for replication and/or expression, e.g., for determination of K_d . Intermediate vectors are typically prokaryote vectors, e.g., plasmids, or shuttle vectors, or insect vectors, for storage or manipulation of the nucleic acid encoding zinc finger protein
10 or production of protein. The nucleic acid encoding a zinc finger protein is also typically cloned into an expression vector, for administration to a plant cell, animal cell, preferably a mammalian cell or a human cell, fungal cell, bacterial cell, or protozoal cell.

To obtain expression of a cloned gene or nucleic acid, a chimeric zinc finger protein is typically subcloned into an expression vector that contains a promoter to
15 direct transcription. Suitable bacterial and eukaryotic promoters are well known in the art and described, e.g., in Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd ed. 1989); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., 1994). Bacterial expression systems for expressing the zinc finger protein are available in, e.g., *E. coli*, *Bacillus sp.*,
20 and *Salmonella* (Palva *et al.*, *Gene* 22:229-235 (1983)). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available.

The promoter used to direct expression of a chimeric zinc finger protein nucleic acid depends on the particular application. For example, a strong constitutive
25 promoter is typically used for expression and purification of zinc finger protein. In contrast, when a zinc finger protein is administered *in vivo* for gene regulation, either a constitutive or an inducible promoter is used, depending on the particular use of the zinc finger protein. The promoter typically can also include elements that are responsive to transactivation, e.g., hypoxia response elements, Gal4 response elements, lac repressor
30 response element, and small molecule control systems such as tet-regulated systems and the RU-486 system (see, e.g., Gossen & Bujard, *Proc. Natl. Acad. Sci. U.S.A.* 89:5547 (1992); Oligino *et al.*, *Gene Ther.* 5:491-496 (1998); Wang *et al.*, *Gene Ther.* 4:432-441

(1997); Neering *et al.*, *Blood* 88:1147-1155 (1996); and Rendahl *et al.*, *Nat. Biotechnol.* 16:757-761 (1998)).

In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required 5 for the expression of the nucleic acid in host cells, either prokaryotic or eukaryotic. A typical expression cassette thus contains a promoter operably linked, e.g., to the nucleic acid sequence encoding the zinc finger protein, and signals required, e.g., for efficient polyadenylation of the transcript, transcriptional termination, ribosome binding sites, or translation termination. Additional elements of the cassette may include, e.g., enhancers, 10 and heterologous spliced intronic signals.

The particular expression vector used to transport the genetic information into the cell is selected with regard to the intended use of the zinc finger protein, e.g., expression in plants, animals, bacteria, fungus, protozoa, etc. Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET23D, 15 and commercially available fusion expression systems such as GST and LacZ. A preferred fusion protein is the maltose binding protein, "MBP." Such fusion proteins are used for purification of the zinc finger protein. Epitope tags can also be added to recombinant proteins to provide convenient methods of isolation, for monitoring expression, and for monitoring cellular and subcellular localization, e.g., c-myc or FLAG.

20 Expression vectors containing regulatory elements from eukaryotic viruses are often used in eukaryotic expression vectors, e.g., SV40 vectors, papilloma virus vectors, and vectors derived from Epstein-Barr virus. Other exemplary eukaryotic vectors include pMSG, pAV009/A+, pMTO10/A+, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV40 25 early promoter, SV40 late promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.

Some expression systems have markers for selection of stably transfected 30 cell lines such as thymidine kinase, hygromycin B phosphotransferase, and dihydrofolate reductase. High yield expression systems are also suitable, such as using a baculovirus vector in insect cells, with a zinc finger protein encoding sequence under the direction of the polyhedrin promoter or other strong baculovirus promoters.

The elements that are typically included in expression vectors also include a replicon that functions in *E. coli*, a gene encoding antibiotic resistance to permit selection of bacteria that harbor recombinant plasmids, and unique restriction sites in nonessential regions of the plasmid to allow insertion of recombinant sequences.

5 Standard transfection methods are used to produce bacterial, mammalian, yeast or insect cell lines that express large quantities of protein, which are then purified using standard techniques (see, e.g., Colley *et al.*, *J. Biol. Chem.* 264:17619-17622 (1989); *Guide to Protein Purification, in Methods in Enzymology*, vol. 182 (Deutscher, ed., 1990)). Transformation of eukaryotic and prokaryotic cells are performed according
10 to standard techniques (see, e.g., Morrison, *J. Bact.* 132:349-351 (1977); Clark-Curtiss & Curtiss, *Methods in Enzymology* 101:347-362 (Wu *et al.*, eds, 1983)).

15 Any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, naked DNA, plasmid vectors, viral vectors, both episomal and integrative, and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Sambrook *et al.*, *supra*). It is only necessary that the particular genetic engineering procedure used be capable of successfully introducing at least one gene into the host cell capable of expressing the
20 protein of choice.

Any suitable method of protein purification known to those of skill in the art can be used to purify the chimeric zinc finger proteins of the invention (see Ausubel, *supra*, Sambrook, *supra*). In addition, any suitable host can be used, e.g., bacterial cells, insect cells, yeast cells, mammalian cells, and the like.

25 In one embodiment, expression of the zinc finger protein fused to a maltose binding protein (MBP-zinc finger protein) in bacterial strain JM109 allows for straightforward purification through an amylose column (NEB). High expression levels of the chimeric zinc finger protein can be obtained by induction with IPTG since the MBP-zinc finger protein fusion in the pMal-c2 expression plasmid is under the control of
30 the IPTG inducible tac promoter (NEB). Bacteria containing the MBP-zinc finger protein fusion plasmids are inoculated in to 2xYT medium containing 10 μ M ZnCl₂, 0.02% glucose, plus 50 μ g/ml ampicillin and shaken at 37°C. At mid-exponential growth IPTG is added to 0.3 mM and the cultures are allowed to shake. After 3 hours the bacteria are

harvested by centrifugation, disrupted by sonication, and then insoluble material is removed by centrifugation. The MBP-zinc finger protein proteins are captured on an amylose-bound resin, washed extensively with buffer containing 20 mM Tris-HCl (pH 7.5), 200 mM NaCl, 5 mM DTT and 50 μ M ZnCl₂, then eluted with maltose in 5 essentially the same buffer (purification is based on a standard protocol from NEB). Purified proteins are quantitated and stored for biochemical analysis.

The biochemical properties of the purified proteins, e.g., K_d, can be characterized by any suitable assay. In one embodiment, K_d is characterized via electrophoretic mobility shift assays ("EMSA") (Buratowski & Chodosh, *in Current* 10 *Protocols in Molecular Biology* pp. 12.2.1-12.2.7 (Ausubel ed., 1996)).

V. Regulatory domains

The chimeric zinc finger proteins made using the methods of the invention can optionally be associated with regulatory domains for modulation of gene expression. 15 The chimeric zinc finger protein can be covalently or non-covalently associated with one or more regulatory domains, alternatively two or more regulatory domains, with the two or more domains being two copies of the same domain, or two different domains. The regulatory domains can be covalently linked to the chimeric zinc finger protein, e.g., via an amino acid linker, as part of a fusion protein. The zinc finger proteins can also be 20 associated with a regulatory domain via a non-covalent dimerization domain, e.g., a leucine zipper, a STAT protein N terminal domain, or an FK506 binding protein (see, e.g., O'Shea, *Science* 254: 539 (1991), Barahmand-Pour *et al.*, *Curr. Top. Microbiol. Immunol.* 211:121-128 (1996); Klemm *et al.*, *Annu. Rev. Immunol.* 16:569-592 (1998); Klemm *et al.*, *Annu. Rev. Immunol.* 16:569-592 (1998); Ho *et al.*, *Nature* 382:822-826 25 (1996); and Pomeranz *et al.*, *Biochem.* 37:965 (1998)). The regulatory domain can be associated with the chimeric zinc finger protein at any suitable position, including the C- or N-terminus of the chimeric zinc finger protein.

Common regulatory domains for addition to the chimeric zinc finger protein made using the methods of the invention include, e.g., heterologous DNA binding 30 domains from transcription factors, effector domains from transcription factors (activators, repressors, co-activators, co-repressors), silencers, nuclear hormone receptors, oncogene transcription factors (e.g., myc, jun, fos, myb, max, mad, rel, ets, bcl, myb, mos

family members etc.); and chromatin associated proteins and their modifiers (e.g., kinases, acetylases and deacetylases).

Transcription factor polypeptides from which one can obtain a regulatory domain include those that are involved in regulated and basal transcription. Such polypeptides include transcription factors, their effector domains, coactivators, silencers, nuclear hormone receptors (see, e.g., Goodrich *et al.*, *Cell* 84:825-30 (1996) for a review of proteins and nucleic acid elements involved in transcription; transcription factors in general are reviewed in Barnes & Adcock, *Clin. Exp. Allergy* 25 Suppl. 2:46-9 (1995) and Roeder, *Methods Enzymol.* 273:165-71 (1996)). Databases dedicated to transcription factors are also known (see, e.g., *Science* 269:630 (1995)). Nuclear hormone receptor transcription factors are described in, for example, Rosen *et al.*, *J. Med. Chem.* 38:4855-74 (1995). The C/EBP family of transcription factors are reviewed in Wedel *et al.*, *Immunobiology* 193:171-85 (1995). Coactivators and co-repressors that mediate transcription regulation by nuclear hormone receptors are reviewed in, for example, Meier, *Eur. J. Endocrinol.* 134(2):158-9 (1996); Kaiser *et al.*, *Trends Biochem. Sci.* 21:342-5 (1996); and Utley *et al.*, *Nature* 394:498-502 (1998)). GATA transcription factors, which are involved in regulation of hematopoiesis, are described in, for example, Simon, *Nat. Genet.* 11:9-11 (1995); Weiss *et al.*, *Exp. Hematol.* 23:99-107. TATA box binding protein (TBP) and its associated TAF polypeptides (which include TAF30, 20 TAF55, TAF80, TAF110, TAF150, and TAF250) are described in Goodrich & Tjian, *Curr. Opin. Cell Biol.* 6:403-9 (1994) and Hurley, *Curr. Opin. Struct. Biol.* 6:69-75 (1996). The STAT family of transcription factors are reviewed in, for example, Barahmand-Pour *et al.*, *Curr. Top. Microbiol. Immunol.* 211:121-8 (1996). Transcription factors involved in disease are reviewed in Aso *et al.*, *J. Clin. Invest.* 97:1561-9 (1996).

In one embodiment, the KRAB repression domain from the human KOX-1 protein is used as a transcriptional repressor (Thiesen *et al.*, *New Biologist* 2:363-374 (1990); Margolin *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 91:4509-4513 (1994); Pengue *et al.*, *Nucl. Acids Res.* 22:2908-2914 (1994); Witzgall *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 91:4514-4518 (1994)). In another embodiment, KAP-1, a KRAB co-repressor, is used with KRAB (Friedman *et al.*, *Genes Dev.* 10:2067-2078 (1996)). Alternatively, KAP-1 can be used alone with a zinc finger protein. Other preferred transcription factors and transcription factor domains that act as transcriptional repressors include MAD (see, e.g., Sommer *et al.*, *J. Biol. Chem.* 273:6632-6642 (1998); Gupta *et al.*, *Oncogene* 16:1149-

1159 (1998); Queva *et al.*, *Oncogene* 16:967-977 (1998); Larsson *et al.*, *Oncogene* 15:737-748 (1997); Laherty *et al.*, *Cell* 89:349-356 (1997); and Cultraro *et al.*, *Mol. Cell. Biol.* 17:2353-2359 (1997)); FKHR (forkhead in rhabdosarcoma gene; Ginsberg *et al.*, *Cancer Res.* 15:3542-3546 (1998); Epstein *et al.*, *Mol. Cell. Biol.* 18:4118-4130 (1998));

5 EGR-1 (early growth response gene product-1; Yan *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 95:8298-8303 (1998); and Liu *et al.*, *Cancer Gene Ther.* 5:3-28 (1998)); the ets2 repressor factor repressor domain (ERD; Sgouras *et al.*, *EMBO J.* 14:4781-4793 ((1995)); and the MAD smSIN3 interaction domain (SID; Ayer *et al.*, *Mol. Cell. Biol.* 16:5772-5781 (1996)).

10 In one embodiment, the HSV VP16 activation domain is used as a transcriptional activator (see, e.g., Hagmann *et al.*, *J. Virol.* 71:5952-5962 (1997)). Other preferred transcription factors that could supply activation domains include the VP64 activation domain (Seipel *et al.*, *EMBO J.* 11:4961-4968 (1996)); nuclear hormone receptors (see, e.g., Torchia *et al.*, *Curr. Opin. Cell. Biol.* 10:373-383 (1998)); the p65 15 subunit of nuclear factor kappa B (Bitko & Barik, *J. Virol.* 72:5610-5618 (1998) and Doyle & Hunt, *Neuroreport* 8:2937-2942 (1997)); and EGR-1 (early growth response gene product-1; Yan *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 95:8298-8303 (1998); and Liu *et al.*, *Cancer Gene Ther.* 5:3-28 (1998)).

20 Kinases, phosphatases, and other proteins that modify polypeptides involved in gene regulation are also useful as regulatory domains for chimeric zinc finger proteins. Such modifiers are often involved in switching on or off transcription mediated by, for example, hormones. Kinases involved in transcription regulation are reviewed in Davis, *Mol. Reprod. Dev.* 42:459-67 (1995), Jackson *et al.*, *Adv. Second Messenger Phosphoprotein Res.* 28:279-86 (1993), and Boulikas, *Crit. Rev. Eukaryot. Gene Expr.* 5:1-77 (1995), while phosphatases are reviewed in, for example, Schonthal & Semin, *Cancer Biol.* 6:239-48 (1995). Nuclear tyrosine kinases are described in Wang, *Trends Biochem. Sci.* 19:373-6 (1994).

25 As described, useful domains can also be obtained from the gene products of oncogenes (e.g., myc, jun, fos, myb, max, mad, rel, ets, bcl, myb, mos family members) and their associated factors and modifiers. Oncogenes are described in, for example, Cooper, *Oncogenes*, 2nd ed., The Jones and Bartlett Series in Biology, Boston, MA, Jones and Bartlett Publishers, 1995. The ets transcription factors are reviewed in Waslylk *et al.*, *Eur. J. Biochem.* 211:7-18 (1993) and Crepieux *et al.*, *Crit. Rev. Oncog.*

5:615-38 (1994). Myc oncogenes are reviewed in, for example, Ryan *et al.*, *Biochem. J.* 314:713-21 (1996). The jun and fos transcription factors are described in, for example, *The Fos and Jun Families of Transcription Factors*, Angel & Herrlich, eds. (1994). The max oncogene is reviewed in Hurlin *et al.*, *Cold Spring Harb. Symp. Quant. Biol.* 59:109-5 16. The myb gene family is reviewed in Kanei-Ishii *et al.*, *Curr. Top. Microbiol. Immunol.* 211:89-98 (1996). The mos family is reviewed in Yew *et al.*, *Curr. Opin. Genet. Dev.* 3:19-25 (1993).

In another embodiment, histone acetyltransferase is used as a transcriptional activator (see, e.g., Jin & Scotto, *Mol. Cell. Biol.* 18:4377-4384 (1998); 10 Wolffe, *Science* 272:371-372 (1996); Taunton *et al.*, *Science* 272:408-411 (1996); and Hassig *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 95:3519-3524 (1998)). In another embodiment, histone deacetylase is used as a transcriptional repressor (see, e.g., Jin & Scotto, *Mol. Cell. Biol.* 18:4377-4384 (1998); Syntichaki & Thireos, *J. Biol. Chem.* 273:24414-24419 (1998); Sakaguchi *et al.*, *Genes Dev.* 12:2831-2841 (1998); and 15 Martinez *et al.*, *J. Biol. Chem.* 273:23781-23785 (1998)).

In addition to regulatory domains, often the chimeric zinc finger protein is expressed as a fusion protein such as maltose binding protein ("MBP"), glutathione S transferase (GST), hexahistidine, c-myc, and the FLAG epitope, for ease of purification, monitoring expression, or monitoring cellular and subcellular localization.

20

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by 25 way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

30

EXAMPLES

The following examples are provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of

noncritical parameters that could be changed or modified to yield essentially similar results.

METHODS

Plasmid construction. Zinc finger expression plasmids used in transfection studies were constructed by PCR amplification of DNA segments encoding the desired fingers of the Zif268 peptide and/or the NRE peptide. These DNA segments were inserted into the HindIII and BamHI sites of pCS, which had been constructed by subcloning an oligonucleotide duplex

5' -AGCTACCATGGCCAAGGAAACCGCAGCTGCCAAAT
10 TCGAAAGACAGCATATGGATTCTAAGCTTCGCGGATCCT-3' (SEQ ID NO: 1)
5' -CTAGAGGATCCCGAAGCTTAGAATCCATATGCTGTCT
TTCGAATTGGCAGCTGCAGTTCCCTGGCCATGGT-3') (SEQ ID NO: 2) into the HindIII and XbaI sites of pcDNA3 (Invitrogen). These expression plasmids were designed to produce zinc finger peptides with both an S-peptide tag (Kim & Raines,
15 *Protein Sci.* 2:348-356(1993); Kim & Raines, *i.* 219:165-166 (1995)) and a nuclear localization signal from SV40 large T-antigen (Kalderon *et al.*, *Cell* 39:499-509 (1984)) at their N-terminus. Reporter plasmid were constructed by site-directed mutagenesis using the QuikChangeTM kit (Stratagene). Construction of the template plasmid (pGL3-TATA/Inr) for the mutagenesis was described previously (Kim & Pabo, *J. Biol. Chem.* 272:29795-29800 (1997)). The DNA sequences of all constructs were confirmed by dideoxy sequencing.

Protein production and purification. The DNA segments encoding the Zif268, NRE, and 268//NRE peptides were amplified by PCR and subcloned into pGEX-6P-3 (Pharmacia). The zinc finger proteins were expressed in *E. coli* as fusions with 25 glutathione S-transferase (GST) and were purified using affinity chromatography according to the manufacturer's protocol. These constructs did not have an S-peptide tag or an SV40 nuclear localization signal. GST was subsequently removed by digestion with PreScissionTM Protease (Pharmacia). Protein concentrations were estimated by using SDS-polyacrylamide gel electrophoresis with bovine serum albumin as a standard
30 (Pomerantz *et al.*, *Science* 267:93-96 (1995)). Concentrations of active zinc finger proteins were determined essentially as described (Rebar & Pabo, *Science* 263:671-673 (1994)). These two methods gave comparable results, indicating that almost all of the protein was active.

Gel shift assay. DNA binding reactions contained the appropriate zinc finger peptide and binding site(s) in a solution of 20 mM bis-Tris propane pH 7.0, 100 mM NaCl, 5 mM MgCl₂, 20 mM ZnSO₄, 10% glycerol, 0.1% Nonidet P40, 5 mM DTT, and 0.10 mg/mL bovine serum albumin in a total volume of 10 mL. All binding 5 experiments were performed at room temperature. The DNA sequences of the binding sites follow: N site, 5'-TCTGC AAGGGTTCA GGCGACACCAACCAA-3' (SEQ ID NO: 3); Z site, 5'-GTGTGTGTGTGATCT GCGTGGGCG GTAAG-3' (SEQ ID NO: 4); NZ site, 5'-TCTGC AAGGGTTCA GCGTGGGCG GTAAG-3' (SEQ ID NO: 5); N/Z site, 5'-TCTGC AAGGGTTCA G GCGTGGGCG GTAAG-3' (SEQ ID NO: 6); and N//Z 10 site, 5'-TCTGC AAGGGTTCA GT GCGTGGGCG GTAAG-3' (SEQ ID NO: 7). In each case, the 9-bp recognition sequences are underlined. Labeled DNAs used in gel shift assays were prepared by Klenow extension or kinase reaction.

To determine dissociation constants, 3-fold serial dilutions of the Zif268 or NRE peptide were incubated with a labeled probe DNA (0.4-1.4 pM) at room temperature 15 for 1 h, and then the reaction mixtures were subjected to gel electrophoresis. The radioactive signals were quantitated by phosphorimager analysis; apparent dissociation constants were determined as described (Rebar & Pabo, *Science* 263:671-673 (1994)).

On-rates and off-rates were also determined by gel shift assay. To initiate the binding reaction when determining on-rate constants, a labeled probe DNA (final 20 concentration, ~0.4 pM) was added to the zinc finger peptide (final concentration, 5-10 pM) at room temperature, and aliquots were analyzed by gel electrophoresis at various time points (0-20 min). The fraction bound at time t was determined by phosphorimager analysis of the gels. The data were then fit (KaleidaGraph™ program (Synergy Software)) to the equation:

$$25 \quad F = F_{\text{final}}[1 - \exp(-k_{\text{obs}} \times t)]$$

where F is the fraction bound at time t; F_{final} is the calculated fraction bound at the completion of the reaction; and k_{obs} is the rate constant (Hoopes *et al.*, *J. Biol. Chem.* 267:11539-11547 (1992)). The on-rate constant was calculated from the equation:

$$30 \quad k_{\text{on}} = (F_{\text{final}} \times k_{\text{obs}})/[P]$$

where [P] is the concentration of the zinc finger protein. Off-rate constants were determined essentially as described (Kim *et al.*, *Proc. Natl. Acad. Sci.*

USA 94:3616-3620 (1997)). Proteins (final concentration, 100 pM) were preincubated with a labeled probe DNA for 1 hour and then a large excess of unlabeled probe DNA (final concentration, 20 nM) was added. Aliquots were removed at various time points and analyzed by gel electrophoresis. The fraction of labeled site was normalized to the fraction found at the end of the 1 hour preincubation period. The natural log of the normalized fraction bound was plotted against time, and the off-rate was determined from the slope. All data points for fast on-rate and off-rate measurements were corrected for the electrophoresis dead time.

Competition binding studies. The 268//NRE peptide (final concentration, 5 pM) was first incubated for 1 hour with various amounts of a cold competitor DNA (0, 0.05, 0.5, 5, and 50 nM), and then the labeled N/Z site (6-8 pM) was added. Samples were analyzed by gel electrophoresis after 2, 24, 48, 96, 190, and 600 hours. Specificity ratios (K_{dc}/K_d) were calculated from the equation:

$$K_{dc}/K_d = \{[C]/[P]_t\} \times (F_0 \times F)/(F_0 - F)(1 - F)$$

where K_{dc} is the dissociation constant for binding to the competitor DNA; K_d is the dissociation constant for binding to the intact chimeric site; [C] is the concentration of competitor DNA; [P]_t is the total concentration of the protein; F₀ is the fraction bound in the absence of the competitor DNA; and F is the fraction bound in the presence of the competitor DNA. This equation assumes that the concentration of free protein is significantly smaller than that of protein bound to DNA. This criterion should readily be satisfied since the K_d of the 268//NRE peptide at the N/Z site is 3.8 fM, and 5 pM of the fusion peptide was used in these competition experiments.

Competition experiments with salmon sperm DNA contained the 268//NRE or Zif268 peptide (200 pM), the labeled N/Z site, and a slight molar excess of unlabeled N/Z site. Various amounts of salmon sperm DNA were added, and samples were analyzed by gel electrophoresis after 2, 24, and 48 hours incubation. When calculating specificity ratios, it was assumed that each base in the salmon sperm DNA represents the beginning of a potential (nonspecific) binding site.

Transient cotransfection assay. The 293 cells were transfected by calcium phosphate precipitation with a glycerol shock as described (Cepek *et al.*, *Genes Dev.* 10:2079-2088 (1996)). Transfection experiments typically used cells at 10-30% confluence in monolayer cultures (6-well plates), and the following plasmids were added: 0.2 mg of the empty expression plasmid (pCS) or of expression plasmids encoding zinc

finger peptides; 0.2 mg of a reporter plasmid; 1 mg of activator plasmid (GAL4-VP16); 0.1 mg of β -galactosidase expression plasmid (pCMVb; Clontech); and 2.5 mg of carrier plasmid (pUC19). The luciferase and β -galactosidase activities in the transfected cells were measured as described (Kim *et al.*, *Proc. Natl. Acad. Sci. USA* 94:3616-3620 5 (1997); Kim & Pabo, *J. Biol. Chem.* 272:29795-29800 (1997)). All the zinc finger peptides expressed in 293 cells were quantitated by using the S.TagTM Rapid Assay kit (Novagen) (Kim & Raines, *Protein Sci.* 2:348-356(1993); Kim & Raines, *Anal. Biochem.* 219:165-166 (1995)).

10

RESULTS

Structure-based design of poly-zinc finger peptides. The design strategy involved linking two three-finger peptides, using longer (noncanonical) linkers at the junction to avoid introducing any strain. To further reduce any risk of interference or collision between the fingers, the linkers were designed so they could accommodate 15 composite binding sites with one or two additional base pairs inserted between the individual 9-bp binding sites. Studies reported in this paper used the three-finger Zif268 peptide (which recognizes the site 5'-GCG TGG GCG-3'; SEQ ID NO: 8) and a three-finger "NRE" peptide (a Zif268 variant previously selected via phage display) that binds tightly and specifically to part of a nuclear hormone response element (5'-AAG GGT 20 TCA-3'; SEQ ID NO: 9) (Greisman & Pabo, *Science* 275:657-661 (1997)). The composite target site with one additional base pair at the center has the sequence 5'-AAG GGT TCA G GCG TGG GCG-3' (SEQ ID NO: 10) and is called the N/Z site (N denotes the binding site for the NRE peptide and Z the binding site for Zif268). The site with two additional base pairs at the center has the sequence 5'-AAG GGT TCA GT GCG TGG 25 GCG-3' (SEQ ID NO: 11) and is called the N//Z site.

Structure-based design, with the Zif268 complex (Pavletich & Pabo, *Science* 252:809-817 (1991); Elrod-Erickson *et al.*, *Structure* 4:1171-1180 (1996)) as a model, was used to determine the appropriate length of linkers for making poly-finger proteins that could recognize each binding site (see Figures 1 and 2). At the N/Z site, it 30 appeared that having 8 residues between the Leu at the α -helical end of the first peptide and the Tyr residue at the first β -sheet of the next peptide would allow sufficient flexibility. A canonical "TGEKP" linker has 4 residues (i.e., Gly-Glu-Lys-Pro) in this

region. At the N//Z site, it seemed reasonable to use 11 residues between the Leu and the Tyr (Fig. 1A). Each linker (Fig. 1A) contained sequences that naturally flank the N-terminus and C-terminus of the three-finger Zif268 peptide. To allow additional flexibility, a glycine was included in the shorter linker (which still is 4 residues longer than a canonical linker), and a Gly-Gly-Gly-Ser sequence was included in the longer linker (which is 7 residues longer than a canonical linker). Using a notation analogous to that for the binding sites, the fusion protein with the shorter linker is denoted as 268/NRE and the fusion protein with the longer linker is denoted as 268//NRE.

Gel shift assays to determine dissociation constants and half-lives of protein-DNA complexes. The Zif268, NRE, and 268//NRE zinc finger peptides were expressed and purified from *E. coli*, and used in several sets of gel shift experiments. A preliminary set of experiments was simply designed to determine whether two three-finger proteins could bind at adjacent 9-bp sites (any interference in binding of the unlinked peptides could reduce the affinity of a poly-finger protein for the composite sites). The first experiments used a DNA fragment (referred to as the NZ site) with the NRE- and Zif 268-binding sites directly juxtaposed (5'-AAG GGT TCA GCG TGG GCG-3'; SEQ ID NO: 12). Various amounts of the NRE peptide were incubated with labeled NZ site in the presence or absence of Zif268 (Figure 3). It was determined that the three-finger NRE peptide actually binds slightly more tightly to the NZ site with prebound Zif268 than to the free site. The apparent dissociation constant (K_d) of the NRE peptide is 180 pM when it binds alone but 60 pM when Zif268 is prebound to the neighboring site. Similar results were obtained at the N/Z site. These experiments prove that there is no collision between peptides bound at adjacent sites and suggest that there may even be some modest cooperative effect. It appears that previous limits in the affinity of poly-finger proteins (Rebar (Ph.D. Thesis), *Selection Studies of Zinc Finger-DNA Recognition*, Massachusetts Institute of Technology (1997); Shi, (Ph.D. Thesis), *Molecular Mechanisms of Zinc Finger Protein-Nucleic Acid Interactions*, Johns Hopkins University (1995); Liu et al., Proc. Natl. Acad. Sci. USA 94:5525-5530 (1997)) were due to problems with linker design.

A second set of binding studies confirms the efficacy of the new linker design. Equilibrium titrations show that the 268//NRE peptide has significantly higher affinity for the composite sites than for the individual 9-bp sites (Table 1). The fusion protein binds to the isolated 9-bp sites with K_d s similar to those of the NRE peptide (180

pM) and the Zif268 peptide (14 pM) for their binding sites. In contrast, the 268//NRE fusion protein binds composite sites so tightly that dissociation constants are too small to readily be determined by protein titration. At least 0.4 pM of labeled probe DNA was needed in these gel shift experiments, making it difficult to accurately determine K_d values of < 1 pM. Given these technical difficulties, it was decided to measure the on-rate and off-rate for binding of the 268//NRE peptide and to use these rates to estimate the equilibrium binding constant (Table 1). Parallel studies with the three-finger peptides provided useful controls. On rates for the 268//NRE, NRE, and Zif268 peptides were fast and were close to the diffusion-controlled limit (108 to 109 M-1s-1) (von Hippel & Berg, 1989). The off rates showed amazing differences: The three-finger peptides have half-lives of < 39 seconds, whereas the 268//NRE peptide has a half-life of 370 hours at the NZ site. Control studies show that the 268//NRE peptide forms a much less stable complex with a single 9-bp site (thus the half-life = 150 seconds at the N site). Both the NRE fingers and the Zif268 fingers must bind their respective 9-bp subsites to form the extraordinarily stable complex observed with the 268//NRE peptide at the NZ site.

In all cases where parallel measurements could be performed, K_d values calculated from the ratio of kinetic constants (k_{off}/k_{on}) were in good agreement with those determined from equilibrium studies (Table 1). This gave confidence in using the kinetic data to determine K_d s in cases where direct titration was impracticable. Calculations show that the 268//NRE peptide has femtomolar affinity for the composite binding sites, with a K_d of 2.1×10^{-15} M (2.1 fM) at the NZ site, 3.7 fM at the N/Z site, and 3.0 fM at the N//Z site (the consistency of these three K_d s also is encouraging since it would be expected that the longer, flexible linker should readily accommodate any of these spacings). The data show that the new linker design is quite effective: the 268//NRE fusion peptide binds far more tightly (5,000-95,000 fold) to the composite site than to the individual 9-bp sites, and it binds far more tightly (6,000-90,000 fold) than either of the original three-finger peptides.

Table 1
Dissociation Constants and Rate Data

Protein	Binding site	K_d , pM	$k_{on} \cdot M^{-1} s^{-1}$	$k_{off} \cdot s^{-1}$
268//NRE	N	190 ± 50	$2.5 \pm 0.4 \times 10^8$	$4.7 \pm 2.9 \times 10^{-3}$
268//NRE	Z	10^*		
268//NRE	NZ	$<1.0 \dagger$	$2.5 \pm 0.2 \times 10^8$	$5.2 \pm 0.9 \times 10^{-7}$
268//NRE	N/Z	$<1.0 \dagger$	$2.5 \pm 0.2 \times 10^8$	$9.2 \pm 0.7 \times 10^{-7}$
268//NRE	N//Z	$<1.0 \dagger$	$2.6 \pm 0.6 \times 10^8$	$7.7 \pm 1.3 \times 10^{-7}$
NRE	N/Z	180 ± 43	$>7.3 \times 10^7$	$>5.9 \times 10^{-2}$
Zif268	NZ	12 ± 3		
Zif268	N/Z	14 ± 4	$>7.0 \times 10^8$	$1.4 \pm 0.4 \times 10^{-2}$
Zif268	N//Z	14 ± 1		

5 All the constants were determined in at least two separate experiments, and the SEM is indicated.

* An exact K_d value could not be determined because this complex gave a smeared band on the gels.

10 † As explained in the text, these K_d values could not be measured directly. Estimating K_d from the ratio k_{off}/k_{on} gives values of 2.1 fM at the NZ site, 3.7 fM at the N/Z site and 3.0 fM at the N//Z site.

Competition experiments were also used to further study the affinity and specificity of the six-finger 268//NRE peptide (Figure 4A). One set of experiments directly tested how well the 9-bp N and Z sites could compete with the composite N/Z site for binding to the fusion peptide. In these experiments, various amounts of cold N or Z site were mixed with a limiting amount of the 268//NRE peptide. After 1 hour of incubation, a slightly molar excess (relative to the total amount of fusion protein) of labeled N/Z site was added. Under these conditions, about 70% of the labeled DNA is shifted in the absence of competitor DNA. Samples taken at various time points were analyzed by gel electrophoresis. Since the 268//NRE peptide concentration in this experiment (5 pM) is a few orders of magnitude higher than the peptide's dissociation constant for the N/Z site, almost all the peptide binds to the N/Z site when no competitor DNA is added. Any decrease in the amount of shifted N/Z site in the presence of competitor DNA reflects binding of the 268//NRE peptide to the competing site.

Equilibration in these experiments requires hundreds of hours, and the stability of the purified protein actually becomes a significant concern (the composite site is added last, and equilibration takes a long time since the fusion protein may encounter cold Z sites hundreds or thousands of times before it first encounters a labeled N/Z site). After pre-equilibration with high concentrations of cold N or Z site, it was determined that the fraction of N/Z label shifted increases steadily with increasing incubation times of up to about 600 hours. After 600 hour of incubation, a significant fraction of the labeled N/Z site is shifted even in the presence of a 10,000-fold molar excess of cold N or Z site. Specificity ratios (calculated as described above) indicate that the 268//NRE peptide prefers the composite site over the N site by a factor of at least 3,800 + 1,600 and that the fusion peptide prefers the composite site over the Z site by a factor of at least 320 + 44. These experiments directly confirm the remarkable specificity of the six-finger peptide, but these values are only lower bounds on the specificity ratios. The protein sample loses some activity during the long incubation time required by these experiments (the activity of the free protein has a half-life of about 2 days under these conditions), and denatured protein will never have a chance to shift the labeled N/Z site.

Competition experiments with salmon sperm DNA were used to estimate the ratio of specific/nonspecific binding constants for the 268//NRE peptide (Figure 4B). These experiments showed that the 268//NRE peptide discriminates very effectively against nonspecific DNA and indicate a specificity ratio (K_{dns}/K_d) of $8.8 + 1.5 \times 10^6$.

Parallel experiments with the three-finger Zif268 peptide give a specificity ratio of $1.2 + 0.1 \times 10^5$. Previous studies, using calf thymus DNA as a competitor and slightly different conditions, had given a specificity ratio of 0.31×10^5 for the Zif268 peptide (Greisman & Pabo, *Science* 275:657-661 (1997)). Taken together, data on the affinity and specificity of the six-finger 268//NRE fusion peptide suggested that it might serve as a very effective repressor and certainly indicated that it would be an excellent candidate for further analysis *in vivo*.

Transient cotransfection studies in the 293 human cell line were used to see whether the new poly-finger peptides could effectively repress transcription from reporter genes. In a previous study, it had been shown that the Zif268 peptide could efficiently repress both basal and VP16-activated transcription when the Zif268 peptide bound to a site near the TATA box or the initiator element (Kim & Pabo, *J. Biol. Chem.* 272:29795-29800 (1997)). In this current study, a luciferase reporter and similar promoter constructs were used in which appropriate binding sites (Z, N, N/Z, and N//Z) were incorporated at comparable positions near the initiator element (Fig. 1B).

It was determined that the 268//NRE peptide gives 72-fold repression of VP16-activated transcription at a promoter containing the N/Z site and 47-fold repression at a promoter containing the N//Z site (Figs. 5A-5D). The 268/NRE peptide gives 68-fold repression at the N/Z site. Clearly, these fusion peptides are very effective repressors at sites with the appropriate spacings. Parallel experiments with the three-finger peptides show repression but indicate that they are considerably less effective than the fusion peptides. Thus the NRE peptide gives 1.9-fold repression with an N site in the promoter; 1.8-fold repression with an N/Z site; 2.7-fold repression with an N//Z site; and no repression with an isolated Z site. The Zif268 peptide gives 13-fold repression from the Z promoter; 8.9-fold repression from the N/Z promoter; 15-fold repression from the N//Z promoter; and no repression with an isolated N site. Further experiments prove that covalent coupling is needed to achieve the much higher repression levels obtained with the fusion proteins at the N/Z site.

Thus co-expressing the Zif268 and NRE peptides as separate polypeptide chains (by including both expression plasmids in the cotransfection assays) gives only 8.5-fold repression at the N/Z site, a level comparable (within experimental error) to the 8.9-fold repression obtained at this site with the isolated Zif268 peptide. This is far less

than the 68-fold and 72-fold repression that the 268/NRE and 268//NRE fusion proteins give at the N/Z site, and it is clear that these "synergistic" effects require covalent linkage.

It is noted that the additional fingers in the fusion peptides may have some modest repressive effects even in cases where only three of the fingers can bind

5 specifically. Thus the six-finger peptides (268/NRE and 268//NRE) give 21 to 23-fold repression from the Z promoter. A similar (22-fold) repression level is obtained with the 268/NRE peptide at the N//Z site. Modeling suggests that the linker is too short to allow specific binding of all six fingers at this site. These repression levels are consistently somewhat higher than the level observed with the isolated Zif268 peptide at the Z site
10 (13-fold repression). It seems possible (when the 268//NRE peptide binds to the Z site) that 1) the NRE fingers are free and yet sterically interfere with assembly of the transcription complex or that 2) the NRE fingers make weak nonspecific contacts with the DNA and thus slightly enhance the stability of the complex. Further studies indicate that all peptides are expressed at comparable levels.

15 The zinc finger peptides expressed in 293 cells had an S-peptide tag, and the amount of peptide was quantitated by using a ribonuclease assay after activating with S-protein (Kim & Raines, *Protein Sci.* 2:348-356(1993); Kim & Raines, *Anal. Biochem.* 219:165-166 (1995)). A conservative estimate indicates that the expression levels of the peptides in cells are significantly higher (at least 100 fold) than the dissociation constants
20 of the three-finger peptides. Plasmids that would encode four- and five-finger variants of the 268/NRE and 268//NRE peptides were also constructed. These were tested in tissue culture transfection studies, and they typically gave repression levels intermediate between those obtained with the three-finger peptides and those obtained with the six-finger peptides (Figs. 5A-5D).

WHAT IS CLAIMED IS:

- 1 1. A method of making a chimeric zinc finger protein that binds to
2 adjacent target sites, the method comprising the steps of:
 - 3 (i) selecting a first and a second DNA-binding domain polypeptide
4 of the chimeric zinc finger protein, wherein at least one of the domains comprises a zinc
5 finger polypeptide, and wherein the first domain binds to a first target site and the second
6 domain binds to a second target site, which target sites are adjacent;
 - 7 (ii) using structure-based design to determine the physical
8 separation between the first and second domains when they are individually bound to the
9 first and second target sites;
 - 10 (iii) selecting a flexible linker that is at least 1-2 Å longer than the
11 physical separation between the first and second domains; and
 - 12 (iv) fusing the first and second domains with the flexible linker,
13 thereby making a chimeric zinc finger protein that binds to adjacent target sites.
- 1 2. The method of claim 1, wherein the flexible linker is at least five
2 amino acids in length.
- 1 3. The method of claim 1, wherein the flexible linker is at least 8
2 amino acids in length.
- 1 4. The method of claim 3, wherein the flexible linker has the amino
2 acid sequence RQKDGERP.
- 1 5. The method of claim 1, wherein the flexible linker is at least 11
2 amino acids in length.
- 1 6. The method of claim 5, wherein the flexible linker has the amino
2 acid sequence RQKDGGGSERP.
- 1 7. The method of claim 1, wherein the adjacent target sites are
2 separated by at least one nucleotide.
- 1 8. The method of claim 1, wherein the adjacent target sites are
2 separated by at least two nucleotides.

1 9. The method of claim 1, wherein the first and the second domains
2 are zinc finger polypeptides.

1 10. The method of claim 9, wherein the zinc finger polypeptide is
2 selected from the group consisting of Zif268 and NRE.

1 11. The method of claim 9, wherein the zinc finger polypeptides are
2 heterologous.

1 12. The method of claim 9, wherein the chimeric zinc finger protein
2 has femtomolar affinity for the adjacent target sites.

1 13. The method of claim 12, wherein the chimeric zinc finger protein
2 has about 2-4 femtomolar affinity for the adjacent target sites.

1 14. The method of claim 1, wherein the first domain is a zinc finger
2 polypeptide and the second domain comprises a heterologous DNA-binding domain
3 polypeptide.

1 15. The method of claim 1, wherein the chimeric zinc finger protein
2 further comprises a regulatory domain polypeptide.

1 16. A method of making a chimeric zinc finger protein that binds to
2 adjacent target sites, the method comprising the steps of:

3 (i) selecting a first and a second DNA-binding domain polypeptide
4 of the chimeric zinc finger protein, wherein at least one of the domains comprises a zinc
5 finger polypeptide, and wherein the first domain binds to a first target site and the second
6 domain binds to a second target site, which target sites are adjacent;

7 (ii) selecting a flexible linker that is five or more amino acids in
8 length; and

9 (iv) fusing the first and second domains with the flexible linker,
10 thereby making a chimeric zinc finger protein that binds to adjacent target sites.

1 17. The method of claim 16, wherein the adjacent target sites are
2 separated by zero nucleotides and the flexible linker is five or six amino acids in length.

1 18. The method of claim 16, wherein the adjacent target sites are
2 separated by one nucleotide and the flexible linker is seven, eight, or nine amino acids in
3 length.

1 19. The method of claim 18, wherein the flexible linker has the amino
2 acid sequence RQKDGERP.

1 20. The method of claim 16, wherein the adjacent target sites are
2 separated by two nucleotides and the flexible linker is ten, eleven, or twelve amino acids
3 in length.

1 21. The method of claim 20, wherein the flexible linker has the amino
2 acid sequence RQKDGGGSERP.

1 22. The method of claim 16, wherein the adjacent target sites are
2 separated by three nucleotides and the flexible linker is twelve or more amino acids in
3 length.

1 23. The method of claim 16, wherein the first and the second domains
2 are zinc finger polypeptides.

1 24. The method of claim 23, wherein the zinc finger polypeptide is
2 selected from the group consisting of Zif268 and NRE.

1 25. The method of claim 23, wherein the zinc finger polypeptides are
2 heterologous.

1 26. The method of claim 23, wherein the chimeric zinc finger protein
2 has femtomolar affinity for the adjacent target sites.

1 27. The method of claim 25, wherein the chimeric zinc finger protein
2 has about 2-4 femtomolar affinity for the adjacent target sites.

1 28. The method of claim 16, wherein the first domain is a zinc finger
2 polypeptide and the second domain comprises a heterologous DNA-binding domain
3 polypeptide.

1 29. The method of claim 16, wherein the chimeric zinc finger protein
2 further comprises a regulatory domain polypeptide.

1 30. A chimeric zinc finger protein that binds to adjacent target sites,
2 the chimeric zinc finger protein comprising:

3 (i) a first and a second DNA-binding domain polypeptide of the
4 chimeric zinc finger protein, wherein at least one of the domains comprises a zinc finger
5 polypeptide, and wherein the first domain binds to a first target site and the second
6 domain binds to a second target site, which target sites are adjacent; and

7 (ii) a flexible linker that is at least 1-2 Å longer than the physical
8 separation between the first and second domains when they are individually bound to the
9 first and second target sites, as determined by structure-based modeling;

10 wherein the first and second domains are fused with the flexible linker.

1 31. The chimeric zinc finger protein of claim 30, wherein the flexible
2 linker is at least five amino acids in length.

1 33. The chimeric zinc finger protein of claim 32, wherein the linker has
2 the amino acid sequence RQKDGERP.

1 35. The chimeric zinc finger protein of claim 34, wherein the linker has
2 the amino acid sequence ROKDGGGSERP.

1 37. The chimeric zinc finger protein of claim 36, wherein the zinc
2 finger polypeptide is selected from the group consisting of Zif268 and NRE

1 38. The chimeric zinc finger protein of claim 36, wherein the zinc
2 finger polypeptides are heterologous.

1 39. The chimeric zinc finger protein of claim 36, wherein the chimeric
2 zinc finger protein has femtomolar affinity for the adjacent target sites.

1 40. The chimeric zinc finger protein of claim 39, wherein the chimeric
2 zinc finger protein has about 2-4 femtomolar affinity for the adjacent target sites.

1 41. The chimeric zinc finger protein of claim 30, wherein the first
2 domain is a zinc finger polypeptide and the second domain comprises a heterologous
3 DNA-binding domain polypeptide.

1 42. The chimeric zinc finger protein of claim 30, wherein the chimeric
2 zinc finger protein further comprises a regulatory domain polypeptide.

1 43. An isolated nucleic acid encoding the chimeric zinc finger protein
2 of claim 30.

1 44. A chimeric zinc finger protein that binds to adjacent target sites,
2 the chimeric zinc finger protein comprising:

3 (i) a first and a second DNA-binding domain polypeptide of the
4 chimeric zinc finger protein, wherein at least one of the domains comprises a zinc finger
5 polypeptide, and wherein the first domain binds to a first target site and the second
6 domain binds to a second target site, which target sites are adjacent; and

7 (ii) a flexible linker that is five or more amino acids in length;
8 wherein the first and second domains are fused with the flexible linker.

1 45. The chimeric zinc finger protein of claim 44, wherein the adjacent
2 target sites are separated by zero nucleotides and the flexible linker is five or six amino
3 acids in length.

1 46. The chimeric zinc finger protein of claim 44, wherein the adjacent
2 target sites are separated by one nucleotide and the flexible linker is seven, eight, or nine
3 amino acids in length.

1 47. The chimeric zinc finger protein of claim 46, wherein the flexible
2 linker has the amino acid sequence RQKDGERP.

1 48. The chimeric zinc finger protein of claim 44, wherein the adjacent
2 target sites are separated by two nucleotides and the flexible linker is ten, eleven, or
3 twelve amino acids in length.

1 49. The chimeric zinc finger protein of claim 48, wherein the flexible
2 linker has the amino acid sequence RQKDGGGSERP.

1 50. The chimeric zinc finger protein of claim 44, wherein the adjacent
2 target sites are separated by three nucleotides and the flexible linker is twelve or more
3 amino acids in length.

1 51. The chimeric zinc finger protein of claim 44, wherein the first and
2 the second domains are zinc finger polypeptides.

1 52. The chimeric zinc finger protein of claim 51, wherein the zinc
2 finger polypeptide is selected from the group consisting of Zif268 and NRE.

1 53. The chimeric zinc finger protein of claim 51, wherein the zinc
2 finger polypeptides are heterologous.



1 54. The chimeric zinc finger protein of claim 51, wherein the chimeric
2 zinc finger protein has femtomolar affinity for the adjacent target sites.

1 55. The chimeric zinc finger protein of claim 54, wherein the chimeric
2 zinc finger protein has about 2-4 femtomolar affinity for the adjacent target sites.

1 56. The chimeric zinc finger protein of claim 44, wherein the first
2 domain is a zinc finger polypeptide and the second domain comprises a heterologous
3 DNA-binding domain polypeptide.

1 57. The chimeric zinc finger protein of claim 44, wherein the chimeric
2 zinc finger protein further comprises a regulatory domain polypeptide.

1 58. An isolated nucleic acid encoding the chimeric zinc finger protein
2 of claim 44.

**FIG. 1A.****FIG. 1B.**




FIG. 2.






FIG. 3.






FIG. 5A.



FIG. 5B.
FIG. 5D.

FIG. 5C.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/04441

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12P 21/06; C07K 14/00; C07H 17/00
US CL :435/69.7; 530/350; 536/23.4

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.7; 530/350; 536/23.4

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	POMERANTZ, J.L. et al. Structure-based design of transcription factors. Science. 06 January 1995, Vol. 267, pages 93-96, see especially page 93 and Fig. 2.	1, 7-10, 12-14, 30, 36-38, 43
-		-----
Y		2, 3, 5, 11, 15-18, 20, 22-29, 31, 32, 34, 39-42, 44-46, 48, 50-58
-		-----
A		4, 6, 19, 21, 33, 35, 47, 49

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance		
B earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*&*	document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
24 MAY 1999	03 JUN 1999
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer <i>Karen Cochrane Carlson</i> KAREN COCHRANE CARLSON, PH.D.
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/04441

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KIM, J.-S. et al. Design of TATA box-binding protein/zinc finger fusions for targeted regulation of gene expression. Proc. Natl. Acad. Sci. USA. April 1997, Vol. 94, pages 3616-3620, see especially page 3617, column 1.	1-3 7, 8, 14, 16-18, 28, 30-32, 41, 43, 44, 56, 58
Y		-----
A		5, 9-13, 15, 20, 22-27, 29, 34-40, 42, 45, 46, 48, 50-55, 57

		4, 6, 19, 21, 33, 35, 47, 49
X	LIU, Q. et al. Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. Proc. Natl. Acad. Sci. USA. May 1997, Vol. 94, pp. 5525-5530, see especially page 5525, column 2.	1, 2, 16, 17, 23-27, 30, 31, 36-38, 43, 44, 51-53, 58
Y		-----
A		3, 5, 7-15, 18, 20, 22, 28, 29, 32, 34, 39-42, 45, 46, 48, 50, 54-57

		4, 6, 19, 21, 33, 35, 47, 49